References
- Baltayiannis G, Baltayiannis N, Tsianos EV. (2008). Suppressors of cytokine signaling as tumor repressors. Silencing of SOCS3 facilitates tumor formation and growth in lung and liver. J BUON 13:263–5
- Cooney RN. (2002). Suppressors of cytokine signaling (SOCS): inhibitors of the JAK/STAT pathway. Shock 17:83–90
- Criniere E, Kaloshi G, Laigle-Donadey F, et al. (2007). MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol 83:173–9
- Esteller M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8:286–98
- Feng Y, Wang Z, Bao Z, et al. (2014). SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients. PLoS One 9:e91829
- Gupta K, Salunke P. (2012). Molecular markers of glioma: an update on recent progress and perspectives. J Cancer Res Clin Oncol 138:1971–81
- Hartmann C, Hentschel B, Wick W, et al. (2010). Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–18
- Houillier C, Wang X, Kaloshi G, et al. (2010). IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560–6
- Jenkins RB, Blair H, Ballman KV, et al. (2006). A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–61
- Jones PA, Baylin SB. (2007). The epigenomics of cancer. Cell 128:683–92
- Kaloshi G, Benouaich-Amiel A, Diakite F, et al. (2007). Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831–6
- Krebs DL, Hilton DJ. (2000). SOCS: physiological suppressors of cytokine signaling. J Cell Sci 113:2813–19
- Kreth S, Thon N, Kreth FW. (2014). Epigenetics in human gliomas. Cancer Lett 342:185–92
- Lindemann C, Hackmann O, Delic S, et al. (2011). SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol 122:241–51
- Louis DN, Ohgaki H, Wiestler OD, et al. (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
- Lu C, Ward PS, Kapoor GS, et al. (2012). IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–8
- Martinez R, Schackert G, Yaya-Tur R, et al. (2007). Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol 83:91–3
- Martini M, Pallini R, Luongo G, et al. (2008). Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer 123:2955–60
- Noushmehr H, Weisenberger DJ, Diefes K, et al. (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–22
- Ricard D, Idbaih A, Ducray F, et al. (2012). Primary brain tumours in adults. Lancet 379:1984–96
- Robertson KD. (2005). DNA methylation and human disease. Nat Rev Genet 6:597–610
- Sadones J, Michotte A, Veld P, et al. (2009). MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 45:146–53
- Shirai K, Siedow MR, Chakravarti A. (2012). Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas. J Oncol 2012:193436
- Stupp R, Mason WP, van den Bent MJ, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987–96
- Turcan S, Rohle D, Goenka A, et al. (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–83
- Uhlmann K, Rohde K, Zeller C, et al. (2003). Distinct methylation profiles of glioma subtypes. Int J Cancer 106:52–9
- Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. (2009). Experience with irinotecan for the treatment of malignant glioma. Neuro-Oncology 11:80–91
- Weber A, Hengge UR, Bardenheuer W, et al. (2005). SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24:6699–708
- Yang P, Wang YZ, Peng XX, et al. (2013). Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neuro-Oncol 113:259–66